Mechanisms of resistance to HER family targeting antibodies.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Experimental Cell Research

• Publication date

  2010-04-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.yexcr.2010.01.009PMID 20064507
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Trastuzumab (Herceptin)

  2011cited by this paper
• Functional genomic analysis identified epidermal growth factor receptor activation as the most common genetic event in oral squamous cell carcinoma.

  2009cited by this paper
• American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy.

  2009cited by this paper
• Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.

  2009influential reference
• Epidermal Growth Factor Receptor cooperates with Src Family Kinases in acquired resistance to cetuximab

  2009cited by this paper
• PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients.

  2009cited by this paper
• An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance

  2009cited by this paper
• Rac1 contributes to trastuzumab resistance of breast cancer cells: Rac1 as a potential therapeutic target for the treatment of trastuzumab-resistant breast cancer

  2009cited by this paper
• PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.

  2009cited by this paper
• A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer.

  2009cited by this paper
• Establishment and Characterization of a Model of Acquired Resistance to Epidermal Growth Factor Receptor Targeting Agents in Human Cancer Cells

  2009cited by this paper
• Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.

  2009cited by this paper
• Nuclear expression of epidermal growth factor receptor is a novel prognostic value in patients with ovarian cancer

  2009cited by this paper
• Nuclear EGFR contributes to acquired resistance to cetuximab

  2009cited by this paper
• PIK3CA Mutations Are Not a Major Determinant of Resistance to the Epidermal Growth Factor Receptor Inhibitor Cetuximab in Metastatic Colorectal Cancer

  2009cited by this paper
• Cetuximab/C225-induced intracellular trafficking of epidermal growth factor receptor.

  2009cited by this paper
• Serum HER‐2/neu and relative resistance to trastuzumab‐based therapy in patients with metastatic breast cancer

  2008cited by this paper
• Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.

  2008cited by this paper
• Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy.

  2008cited by this paper
• Combined lapatinib and cetuximab enhance cytotoxicity against gefitinib-resistant lung cancer cells

  2008cited by this paper
• A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment

  2008cited by this paper
• Synergy between cetuximab and chemotherapy in tumors of the gastrointestinal tract.

  2008cited by this paper
• Association of epidermal growth factor receptor (EGFR) gene copy number amplification with neck lymph node metastasis in areca-associated oral carcinomas.

  2008cited by this paper
• K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

  2008cited by this paper
• Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer.

  2008cited by this paper
• EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer.

  2008cited by this paper
• U.S. Food and Drug Administration Approval: Panitumumab for Epidermal Growth Factor Receptor–Expressing Metastatic Colorectal Carcinoma with Progression Following Fluoropyrimidine-, Oxaliplatin-, and Irinotecan-Containing Chemotherapy Regimens

  2008cited by this paper
• The Catalogue of Somatic Mutations in Cancer (COSMIC)

  2008cited by this paper
• Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells (Cancer Research (2005) 65, (11118-11128))

  2008cited by this paper
• KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience

  2008cited by this paper
• Nuclear epidermal growth factor receptor (EGFR) interacts with signal transducer and activator of transcription 5 (STAT5) in activating Aurora-A gene expression

  2008cited by this paper
• Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG)

  2008cited by this paper
• KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience

  2008cited by this paper
• Correlates and Determinants of Nuclear Epidermal Growth Factor Receptor Content in an Oropharyngeal Cancer Tissue Microarray

  2008influential reference
• A Prospective Study of Dietary Folate and Vitamin B and Colon Cancer According to Microsatellite Instability and KRAS Mutational Status

  2008cited by this paper
• Platinum-based chemotherapy plus cetuximab in head and neck cancer.

  2008influential reference
• KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab.

  2008cited by this paper
• Epidermal growth factor receptor: a novel biomarker for aggressive head and neck cutaneous squamous cell carcinoma.

  2008cited by this paper
• Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins.

  2008cited by this paper
• Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells.

  2008cited by this paper
• Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members

  2008influential reference
• Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy

  2007cited by this paper
• A novel mechanism of resistance to epidermal growth factor receptor antagonism in vivo.

  2007cited by this paper
• Human Breast Cancer Cells Selected for Resistance to Trastuzumab In vivo Overexpress Epidermal Growth Factor Receptor and ErbB Ligands and Remain Dependent on the ErbB Receptor Network

  2007cited by this paper
• Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer

  2007cited by this paper
• Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab.

  2007cited by this paper
• Cetuximab for the treatment of colorectal cancer.

  2007cited by this paper
• Antibody-Dependent Cellular Cytotoxicity Mediated by Cetuximab against Lung Cancer Cell Lines

  2007cited by this paper
• MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

  2007cited by this paper
• Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.

  2007cited by this paper
• Characterization of a Novel Tripartite Nuclear Localization Sequence in the EGFR Family*

  2007cited by this paper
• Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study.

  2007cited by this paper
• Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab.

  2007cited by this paper
• The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis

  2007cited by this paper
• Role of the Sec61 translocon in EGF receptor trafficking to the nucleus and gene expression.

  2007cited by this paper
• Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer.

  2007cited by this paper
• Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.

  2007cited by this paper
• Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival.

  2006cited by this paper
• Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers.

  2006cited by this paper
• Signaling via ErbB2 and ErbB3 Associates with Resistance and Epidermal Growth Factor Receptor (EGFR) Amplification with Sensitivity to EGFR Inhibitor Gefitinib in Head and Neck Squamous Cell Carcinoma Cells

  2006cited by this paper
• Nuclear EGFR signalling network in cancers: linking EGFR pathway to cell cycle progression, nitric oxide pathway and patient survival

  2006cited by this paper
• HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients.

  2006cited by this paper
• Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.

  2006influential reference
• Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas.

  2006cited by this paper
• Nuclear‐cytoplasmic transport of EGFR involves receptor endocytosis, importin β1 and CRM1

  2006cited by this paper
• Co‐regulation of B‐Myb expression by E2F1 and EGF receptor

  2006influential reference
• HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy

  2006cited by this paper
• Biosynthesis of tumorigenic HER2 C‐terminal fragments by alternative initiation of translation

  2006cited by this paper
• EGFR signaling pathway in breast cancers: from traditional signal transduction to direct nuclear translocalization

  2006cited by this paper
• Mutant Epidermal Growth Factor Receptor (EGFRvIII) Contributes to Head and Neck Cancer Growth and Resistance to EGFR Targeting

  2006cited by this paper
• KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

  2006influential reference
• Strategies for Delaying or Treating In vivo Acquired Resistance to Trastuzumab in Human Breast Cancer Xenografts

  2006cited by this paper
• Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer

  2006cited by this paper
• Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines.

  2006cited by this paper
• Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer.

  2006cited by this paper
• Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.

  2006cited by this paper
• EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus

  2006cited by this paper
• Tyrosine phosphorylation controls PCNA function through protein stability

  2006cited by this paper
• Anti‐tumor activity of the combination of cetuximab, an anti‐EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases

  2006cited by this paper
• “Oncogenic Shock”: Explaining Oncogene Addiction through Differential Signal Attenuation

  2006cited by this paper
• Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

  2006cited by this paper
• Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells.

  2005cited by this paper
• Frequencies of HER-2/neu expression and gene amplification in patients with oesophageal squamous cell carcinoma

  2005cited by this paper
• Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study.

  2005cited by this paper
• Novel prognostic value of nuclear epidermal growth factor receptor in breast cancer.

  2005cited by this paper
• Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.

  2005cited by this paper
• Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

  2005cited by this paper
• TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers.

  2005cited by this paper
• Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway.

  2005cited by this paper
• ERBB Receptors and Cancer: The Complexity of Targeted Inhibitors

  2005cited by this paper
• Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.

  2005cited by this paper
• Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients.

  2005cited by this paper
• Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations.

  2005cited by this paper
• TGFalpha expression impairs Trastuzumab-induced HER2 downregulation.

  2005cited by this paper
• ERBB receptors and cancer: the complexity of targeted inhibitors

  2005cited by this paper
• Loss of RALT/MIG-6 expression in ERBB2-amplified breast carcinomas enhances ErbB-2 oncogenic potency and favors resistance to Herceptin

  2005cited by this paper
• Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line.

  2005influential reference
• Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

  2005cited by this paper
• Tissue Microarray Analysis of C-MYC Oncogene Copy Number Changes in Larynx Carcinoma

  2005cited by this paper
• Quantitative Determination of Nuclear and Cytoplasmic Epidermal Growth Factor Receptor Expression in Oropharyngeal Squamous Cell Cancer by Using Automated Quantitative Analysis

  2005influential reference

• Advancements in Targeted Therapies for Colorectal Cancer: Overcoming Challenges and Exploring Future Directions

  2025cites this paper
• BiSpec Pairwise AI: guiding the selection of bispecific antibody target combinations with pairwise learning and GPT augmentation

  2024cites this paper
• Pathogenic HER3 dimerization domain mutations create a structural bias towards un-conventional EGFR-HER3 signalling axis in breast cancer.

  2023cites this paper
• Frequent overexpression of HER3 in brain metastases from breast and lung cancer.

  2023cites this paper
• The Role of Tumor-Associated Antigen HER2/neu in Tumor Development and the Different Approaches for Using It in Treatment: Many Choices and Future Directions

  2022influential citation
• Effects of H2O2 Treatment Combined With PI3K Inhibitor and MEK Inhibitor in AGS Cells: Oxidative Stress Outcomes in a Model of Gastric Cancer

  2022cites this paper
• Differences in genomic profile of high-grade urothelial carcinoma according to tumor location.

  2021cites this paper
• A scDb-based trivalent bispecific antibody for T-cell-mediated killing of HER3-expressing cancer cells

  2021cites this paper
• Fc-comprising scDb-based trivalent, bispecific T-cell engagers for selective killing of HER3-expressing cancer cells independent of cytokine release

  2021cites this paper
• Enhanced Antitumor Effect of Trastuzumab and Duligotuzumab or Ipatasertib Combination in HER-2 Positive Gastric Cancer Cells

  2021cites this paper
• Neuregulin Signaling in the Tumor Microenvironment.

  2021cites this paper
• Natural tyrosine kinase inhibitors acting on the epidermal growth factor receptor: Their relevance for cancer therapy.

  2020cites this paper
• Mechanisms of Action of EGFR Tyrosine Kinase Receptor Incorporated in Extracellular Vesicles

  2020cites this paper
• Current Development of Monoclonal Antibodies in Cancer Therapy.

  2020cites this paper
• Ibrutinib as a potential therapeutic option for HER2 overexpressing breast cancer – the role of STAT3 and p21

  2019cites this paper
• Ligand-Independent EGFR Activation by Anchorage-Stimulated Src Promotes Cancer Cell Proliferation and Cetuximab Resistance via ErbB3 Phosphorylation

  2019cites this paper
• Activation of the cGMP/protein kinase G system in breast cancer by the dopamine receptor-1

  2019cites this paper
• Receptor tyrosine kinases in PI3K signaling: The therapeutic targets in cancer.

  2019cites this paper
• 1 Ligand-Independent EGFR Activation by Anchorage 2 Stimulated Src Promotes Cancer Cell Proliferation 3 and Cetuximab Resistance via ErbB 3 Phosphorylation 4

  2019cites this paper
• Antibody‐drug conjugates: Promising and efficient tools for targeted cancer therapy

  2018cites this paper
• Fisetin induces apoptosis in breast cancer MDA‐MB‐453 cells through degradation of HER2/neu and via the PI3K/Akt pathway

  2018cites this paper
• NEXT-GENERATION SEQUENCING AND MOTIF GRAFTING APPLICATIONS IN SYNTHETIC ANTIBODY DISCOVERY

  2018cites this paper
• Hersintuzumab: A novel humanized anti-HER2 monoclonal antibody induces potent tumor growth inhibition

  2018cites this paper
• HER3 signaling and targeted therapy in cancer

  2018cites this paper
• Expression of MT4-MMP, EGFR, and RB in Triple-Negative Breast Cancer Strongly Sensitizes Tumors to Erlotinib and Palbociclib Combination Therapy

  2018cites this paper
• Epidermal growth factor receptor peptide vaccination induces cross-reactive immunity to human EGFR, HER2, and HER3

  2018cites this paper
• Phase I Study of Chimeric Antigen Receptor-Modified T Cells in Patients with 1 EGFR-positive Advanced Biliary Tract Cancers 2

  2017cites this paper
• Integrating imaging, exosome and protein network rewiring information to track early tumour evolution of resistance mechanisms

  2017cites this paper
• Inhibition of HER3 activation and tumor growth with a human antibody binding to a conserved epitope formed by domain III and IV

  2017cites this paper
• Proteins Involved in HER2 Signalling Pathway, Their Relations and Influence on Metastasis-Free Survival in HER2-Positive Breast Cancer Patients Treated with Trastuzumab in Adjuvant Setting

  2017cites this paper
• Dacomitinib, a pan-inhibitor of ErbB receptors, suppresses growth and invasive capacity of chemoresistant ovarian carcinoma cells

  2017cites this paper
• Phase I Study of Chimeric Antigen Receptor–Modified T Cells in Patients with EGFR-Positive Advanced Biliary Tract Cancers

  2017cites this paper
• ERBB3: A potential serum biomarker for early detection and therapeutic target for devil facial tumour 1 (DFT1)

  2017cites this paper
• Tumor angiogenesis revisited: Regulators and clinical implications

  2017cites this paper
• SP1 promotes tumor angiogenesis and invasion by activating VEGF expression in an acquired trastuzumab-resistant ovarian cancer model

  2017cites this paper
• Combinatorial Protein Engineering Of Affibody Molecules Using E. Coli Display And Rational Design Of Affibody-Based Tracers For Medical Imaging

  2017cites this paper
• ffi cient [ 18 F ] AlF Radiolabeling of ZHER 3 : 8698 A ffi body Molecule for Imaging of HER 3 Positive Tumors

  2016cites this paper
• Toward the use of precision medicine for the treatment of head and neck squamous cell carcinoma

  2016cites this paper
• Preclinical evidence of multiple mechanisms underlying trastuzumab resistance in gastric cancer

  2016cites this paper
• Phase I trial of dacomitinib, a pan-human epidermal growth factor receptor (HER) inhibitor, with concurrent radiotherapy and cisplatin in patients with locoregionally advanced squamous cell carcinoma of the head and neck (XDC-001)

  2016cites this paper
• Efficient [(18)F]AlF Radiolabeling of ZHER3:8698 Affibody Molecule for Imaging of HER3 Positive Tumors.

  2016cites this paper
• MiR-331-3p inhibits proliferation and promotes apoptosis by targeting HER2 through the PI3K/Akt and ERK1/2 pathways in colorectal cancer.

  2016cites this paper
• Anti-HER3 Monoclonal Antibody Inhibits Acquired Trastuzumab-Resistant Gynecologic Cancers

  2016cites this paper
• Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations.

  2016cites this paper
• Pan‐HER—An antibody mixture targeting EGFR, HER2 and HER3 abrogates preformed and ligand‐induced EGFR homo‐ and heterodimers

  2016cites this paper
• Peptide-conjugated PEGylated PAMAM as a highly affinitive nanocarrier towards HER2-overexpressing cancer cells

  2016cites this paper
• Comparative evaluation of 111In-labeled NOTA‑conjugated affibody molecules for visualization of HER3 expression in malignant tumors.

  2015cites this paper
• Four-in-one antibodies have superior cancer inhibitory activity against EGFR, HER2, HER3, and VEGF through disruption of HER/MET crosstalk.

  2015cites this paper
• Anthracyclines/trastuzumab: new aspects of cardiotoxicity and molecular mechanisms.

  2015cites this paper
• Novel syngeneic mouse mammary carcinoma cell lines from aggressive ErbB2/Neu-overexpressing/PTEN-deficient tumors.

  2015cites this paper
• Cancer Immunotherapy: More Is (Much) Better

  2015cites this paper
• Trastuzumab-induced HER 2 phosphorylation : exploring the mechanisms and implications

  2015cites this paper
• Antibody-targeted drugs and drug resistance--challenges and solutions.

  2015cites this paper
• Natural Product Modulators to Overcome Multidrug Resistance In Cancer

  2015cites this paper
• Examination of HER3 targeting in cancer using monoclonal antibodies

  2015cites this paper
• Correlation analysis of hormone receptors and the expressions of HER-2 and Ki-67 in breast cancer.

  2015cites this paper
• Targeting of erbB3 receptor to overcome resistance in cancer treatment

  2014cites this paper
• Synergy effects of herb extracts: pharmacokinetics and pharmacodynamic basis.

  2014cites this paper
• Imaging of HER3-expressing xenografts in mice using a 99mTc(CO)3-HEHEHE-ZHER3:08699 affibody molecule

  2014cites this paper
• Tetraspecific ligand for tumor-targeted delivery of nanomaterials.

  2014cites this paper
• Dual targeting of ErbB-2/ErbB-3 results in enhanced antitumor activity in preclinical models of pancreatic cancer

  2014cites this paper
• miR-143 and miR-145 synergistically regulate ERBB3 to suppress cell proliferation and invasion in breast cancer

  2014influential citation
• Trastuzumab-induced HER2 phosphorylation: exploring the mechanisms and implications

  2014cites this paper
• HER2/neu: an increasingly important therapeutic target. Part 1: basic biology & therapeutic armamentarium

  2014cites this paper
• Radiation Oncology In Vitro: Trends to Improve Radiotherapy through Molecular Targets

  2014cites this paper
• Selection of DNA aptamers against epidermal growth factor receptor with high affinity and specificity.

  2014cites this paper
• Role of erbB3 receptors in cancer therapeutic resistance.

  2014cites this paper
• Unmet needs and challenges in gastric cancer: the way forward.

  2014cites this paper
• A FcγRIII-engaging bispecific antibody expands the range of HER2-expressing breast tumors eligible to antibody therapy

  2014cites this paper
• A dual tyrosine kinase inhibitor lapatinib suppresses overexpression of matrix metallopeptidase 1 (MMP1) in endometrial cancer

  2014cites this paper
• RG7116, a therapeutic antibody that binds the inactive HER3 receptor and is optimized for immune effector activation.

  2013cites this paper
• Human epidermal growth factor receptor 2-positive breast cancer: which cytotoxic agent best complements trastuzumab’s efficacy in vitro?

  2013cites this paper
• Thyroid cancer cell resistance to gefitinib depends on the constitutive oncogenic activation of the ERK pathway.

  2013cites this paper
• ErbB receptors and their growth factor ligands in pediatric intestinal inflammation

  2013cites this paper
• Complex Role of CD 4 + T Cells Initiated Antitumor Responses Require the − Effective Anti-Neu

  2013cites this paper
• Effect of Oxaliplatin, Fluorouracil, and Leucovorin With or Without Cetuximab on Survival Among Patients With Resected Stage III Colon Cancer

  2013cites this paper
• Anti-HER3 domain 1 and 3 antibodies reduce tumor growth by hindering HER2/HER3 dimerization and AKT-induced MDM2, XIAP, and FoxO1 phosphorylation.

  2013cites this paper
• Human epidermal growth factor receptor 2-positive breast cancer: which cytotoxic agent best complements trastuzumab’s efficacy in vitro?

  2013cites this paper
• A phase II trial of dacomitinib , an oral pan-human EGF receptor ( HER ) inhibitor , as fi rst-line treatment in recurrent and / or metastatic squamous-cell carcinoma of the head and neck †

  2013cites this paper
• Antitumor activity of a monoclonal antibody targeting major histocompatibility complex class I-Her2 peptide complexes.

  2013cites this paper
• Current approaches and future directions in the treatment of HER2-positive breast cancer.

  2013cites this paper
• Effective Anti-Neu–Initiated Antitumor Responses Require the Complex Role of CD4+ T Cells

  2013cites this paper
• Design of a Phase I Clinical Trial to evaluate intra-tumoral delivery of ErbB-targeted CAR T-cells in locally advanced or recurrent Head and Neck Cancer

  2013cites this paper
• Adaptive Immune Responses and HER2/neu-Positive Breast Cancer

  2013cites this paper
• Construction and characterization of a new chimeric 1 antibody against HER 2

  2013cites this paper
• Epidermal growth factor‐induced cellular invasion requires sphingosine‐1‐phosphate/sphingosine‐1‐phosphate 2 receptor‐mediated ezrin activation

  2013cites this paper
• Predictors of response in locally advanced rectal cancer following concurrent chemoradiotherapy

  2013cites this paper
• Survival of HER2-Positive Breast Cancer Cells: Receptor Signaling to Apoptotic Control Centers.

  2013cites this paper
• The dark side of stem cells: triggering cancer progression by cell fusion.

  2013cites this paper
• Role of phospholipase C in cell invasion and metastasis.

  2013cites this paper
• A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck.

  2013cites this paper
• Antitumor effects of EGFR antisense guanidine-based peptide nucleic acids in cancer models.

  2013cites this paper
• Cancer Therapy : Preclinical Effective Anti-Neu – Initiated Antitumor Responses Require the Complex Role of CD 4 þ T Cells

  2013cites this paper
• Precis : As a central integrator of the EGF family receptor system in cancer , HER 3 offers an appealing therapeutic target in many types of human cancer

  2013cites this paper
• Importance of HER2/NEU (C-ERB-B2) Status in Breast Cancer: Which Method is More Effective to Evaluate of HER-2 Status? Meme Kanserinde HER-2/NEU (C-ERB-B2) Durumunun Önemi: Hangi Yöntemle Değerlendirmek Daha Uygun?

  2013cites this paper
• Design of a Phase I Clinical Trial to Evaluate Intratumoral Delivery of ErbB-Targeted Chimeric Antigen Receptor T-Cells in Locally Advanced or Recurrent Head and Neck Cancer

  2013cites this paper
• THERAPEUTIC POTENTIAL OF EGFR DERIVED PEPTIDES IN BREAST CANCER

  2013cites this paper
• Heavy Chain Only Antibodies: A New Paradigm in Personalized HER2+ Breast Cancer Therapy.

  2013cites this paper
• Therapeutics , Targets , and Chemical Biology RG 7116 , a Therapeutic Antibody That Binds the Inactive HER 3 Receptor and Is Optimized for Immune Effector Activation

  2013cites this paper
• The in vitro influences of epidermal growth factor and heregulin-β1 on the efficacy of trastuzumab used in Her-2 positive breast adenocarcinoma

  2013cites this paper